U.S. Markets closed

Breakfast Technical Briefing on Amarin and Three Other Additional Biotech Stocks

Stock Research Monitor: ACHN, ATNM, and APRI

LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on AMRN sign up now at www.wallstequities.com/registration. On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of last Friday's session. The NASDAQ Composite ended the day at 7,510.30, up 0.09%; the Dow Jones Industrial Average edged 0.23% higher, to finish at 24,271.41; and the S&P 500 closed at 2,718.37, up 0.08%. This Monday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), and Apricus Biosciences Inc. (NASDAQ: APRI). All you have to do is sign up today for this free limited time offer by clicking the link below.


Achillion Pharmaceuticals

On Friday, shares in New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc. recorded a trading volume of 674,087 shares. The stock ended the session 1.05% lower at $2.83. The stock is trading below its 50-day moving average by 16.00%. Moreover, shares of Achillion Pharma, which discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the US, have a Relative Strength Index (RSI) of 36.74. Get the full research report on ACHN for free by clicking below at:


Actinium Pharmaceuticals

New York-based Actinium Pharmaceuticals Inc.'s stock closed the day 0.78% lower at $0.64 with a total trading volume of 1.02 million shares. The Company's shares have advanced 66.28% in the past month and 76.99% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 49.08% and 15.26%, respectively. Additionally, shares of Actinium Pharma, which develops targeted therapies for patients with cancers lacking effective treatment options, have an RSI of 64.96. ATNM's complimentary research coverage is a few simple steps away at:



Shares in Dublin, Ireland-based Amarin Corp. PLC recorded a trading volume of 4.43 million shares, which was above their three months average volume of 2.12 million shares. The stock ended last Friday's trading session 1.98% higher at $3.09. The Company's shares have advanced 5.82% over the previous three months. The stock is trading below its 50-day moving average by 0.60%. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 50.17. Register for your free research report on AMRN at:


Apricus Biosciences

San Diego, California headquartered Apricus Biosciences Inc.'s stock finished Friday's session 4.85% lower at $0.39 with a total trading volume of 976,818 shares. The Company's shares have advanced 39.29% in the last month. The stock is trading above its 50-day moving average by 24.45%. Additionally, shares of Apricus Biosciences, which focuses on the development of product candidates in the areas of urology and rheumatology, have an RSI of 54.52. Wall St. Equities' downloadable research report on APRI available at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities